GSK posts blowout RSV vaccine sales, raises outlook
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Dado Ruvic | ReutersGlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine.The shot targeting the severe and in some cases life-threatening virus booked around £1.2 billion, or...